VeriSIM Life, Total Brain to develop drugs for broad range of neurological disorders

VeriSIM Life, a Serra Capital company, announced this week that it was partnering with Total Brain to develop new drugs for the treatment of a wide array of neurological disorders. This collaboration will integrate VerisSIM’s BIOSIM artificial intelligence-enabled drug development decision engine with Total Brain’s mental health and brain performance database to develop new therapies.

“We are excited to partner with Total Brain to combine the power of their high-dimensional data with our drug prediction engine to open new doors for drug discovery specifically addressing neurological conditions — something that has never been explored this way before,” Jo Varshney, PhD, founder and CEO of VeriSIM Life.